Cargando…
A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders
The release of corifollitropin alfa simplifies daily injections of short-acting recombinant follicular stimulating hormone (rFSH), and its widely-used protocol involves short-acting gonadotropins supplements and a fixed GnRH antagonist regimen, largely based on follicle size. In this study, the feas...
Autores principales: | Wang, Huai-Ling, Lai, Hsing-Hua, Chuang, Tzu-Hsuan, Shih, Yu-Wei, Huang, Shih-Chieh, Lee, Meng-Ju, Chen, Shee-Uan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839605/ https://www.ncbi.nlm.nih.gov/pubmed/27100388 http://dx.doi.org/10.1371/journal.pone.0154123 |
Ejemplares similares
-
Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients
por: Selman, Helmy, et al.
Publicado: (2016) -
Corifollitropin alfa for poor responders patients, a prospective randomized study
por: Fusi, F. M., et al.
Publicado: (2020) -
Association of progesterone production with serum anti-Müllerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa
por: Lee, Tsung-Hsien, et al.
Publicado: (2018) -
Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol
por: Huang, Ting-Chi, et al.
Publicado: (2021) -
Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
por: Huang, Chen-Yu, et al.
Publicado: (2020)